Dr. med.
Malte Wehmeyer
  • Facharzt
  • Facharzt für Innere Medizin



Hauptgebäude O10 , 2. Etage, Raumnummer
Deutsch (Muttersprache)



  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells
Zecher B, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick M, Yuki Y, Martin M, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller L, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer M, Poch T, Sebode M, , Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer K, Schumacher U, Sauter G, Carrington M, Franke A, Bunders M, Schramm C, Altfeld M
GUT. 2024;73(2):325-337.

Mini-laparoscopy as a diagnostic tool for abdominal tuberculosis: a retrospective series of 29 cases
Brehm T, Ndzedzeka-Völz N, Wehmeyer M, Christner M, Clauditz T, Hübener P, Addo M, Lohse A, Schmiedel S
SURG ENDOSC. 2023;37(3):1830-1837.

Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis
Johannes H, Malte W, Alali S, Marcial S, Sören W, Ptashynska A, Christina W, Christoph S, Willhelm L, Till K, Jörg S
LIVER INT. 2023;43(6):1269-1276.

TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD
Liebold I, Meyer S, Heine M, Kuhl A, Witt J, Eissing L, Fischer A, Koop A, Kluwe J, Wiesch J, Wehmeyer M, Knippschild U, Scheja L, Heeren J, Bosurgi L, Worthmann A
CELLS-BASEL. 2023;12(3):.

SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients
Ruether D, Schaub G, Duengelhoef P, Haag F, Brehm T, Fathi A, Wehmeyer M, Jahnke-Triankowski J, Mayer L, Hoffmann A, Fischer L, Addo M, Lütgehetmann M, Lohse A, Schulze Zur Wiesch J, Sterneck M
CLIN GASTROENTEROL H. 2022;20(1):162-172.e9.

Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial
Wehmeyer M, Horvatits T, Buchholz A, Krause L, Walter S, Zapf A, Lohse A, Kluwe J
TRIALS. 2022;23(1):302.

Frequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis
Wehmeyer M, Sekhri H, Wroblewski R, Galante A, Meyer T, Lohse A, Schulze Zur Wiesch J
PLOS ONE. 2022;17(7):.

Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis
Drolz A, Schramm C, Seiz O, Groth S, Vettorazzi E, Horvatits T, Wehmeyer M, Schramm C, Goeser T, Roesch T, Lohse A, Kluwe J
ENDOSCOPY. 2021;53(3):226-234.

Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
Drolz A, Wolter S, Wehmeyer M, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse A, Mann O, Kluwe J
INT J OBESITY. 2021;45(10):2197-2204.

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era
Piecha F, Gänßler J, Ozga A, Wehmeyer M, Kluwe J, Lampalzer S, Creutzfeldt A, Buescher G, Horvatits T, Sterneck M, Pischke S, Lohse A, Schulze Zur Wiesch J
SCAND J GASTROENTERO. 2021;56(7):840-848.

Editorial: only steps away from prime time? Hepatitis B virus RNA as routine marker to guide HBV treatment decisions
Wehmeyer M, Schulze zur Wiesch J
ALIMENT PHARM THER. 2021;54(7):970-971.

High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection:longitudinal analysis of a German cohort:longitudinal analysis of a German cohort
Bockmann J, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, Giersch K, Hall M, Murray J, Dandri M, Lüth S, Lohse A, Lütgehetmann M, Schulze Zur Wiesch J
BMC GASTROENTEROL. 2020;20(1):24.

Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era
Ingiliz P, Wehmeyer M, Boesecke C, Schulze Zur Wiesch J, Schewe K, Lutz T, Baumgarten A, Simon K, Hueppe D, Rockstroh J, Mauss S, Christensen S
CLIN INFECT DIS. 2020;71(5):1248-1254.

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
Koop A, Thiele N, Steins D, Michaëlsson E, Wehmeyer M, Scheja L, Steglich B, Huber S, Schulze zur Wiesch J, Lohse A, Heeren J, Kluwe J
HEPATOL COMMUN. 2020;4(10):1441-1458.

Treatment and re-treatment results of HCV patients in the DAA era
Piecha F, Gänßler J, Ozga A, Wehmeyer M, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse A, Schulze Zur Wiesch J
PLOS ONE. 2020;15(5):e0232773.

Einsatz von Protonenpumpenhemmern bei Patienten mit Leberzirrhose – eine Umfrage unter Hepatologen in Deutschland
Horvatits T, Drolz A, Wehmeyer M, Steib C, Trebicka J, Lohse A, Kluwe J
Z GASTROENTEROL. 2019;57(6):729-733.

Severe Acute Liver Injury Following Therapeutic Doses of Acetaminophen in a Patient With Spinal Muscular Atrophy
Brehm T, Wehmeyer M, Fuhrmann V, Schäfer H, Kluwe J
AM J THER. 2018;26(4):e528-e529.

Kombination von NAFLD Fibrosis Score und transienter Elastografie zur Identifikation mittelgradiger Fibrosestadien (II/III) bei nicht-alkoholischer Fettlebererkrankung
Drolz A, Wehmeyer M, Diedrich T, Piecha F, Schulze Zur Wiesch J, Kluwe J
Z GASTROENTEROL. 2018;56(1):43-50.

Persistierender Aszites nach TIPS-Implantation ist prädiktiv für ein geringeres transplantationsfreies Überleben bei Patienten mit Leberzirrhose
Piecha F, Steins D, Drolz A, Wehmeyer M, Horvatits T, Spink C, Ittrich H, Lohse A, Kluwe J
2018. Abstractband GASL 2018. 2018. Aufl. Thieme Deutschlnad, .

Time trend of reported cases and publications: hepatitis E in comparison to hepatitis A - D in Germany from 2001 to 2016
Wehmeyer M, Hartl J, von Wulffen M, Lohse A, Pischke S
Z GASTROENTEROL. 2018;56(1):29-35.

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)
Wehmeyer M, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon K, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J
J MED VIROL. 2018;90(2):304-312.

Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort
Dammermann W, Polywka S, Dettmann I, Mindorf S, Komorowski L, Wehmeyer M, Schulze Zur Wiesch J, Stöcker W, Lüth S
MED MICROBIOL IMMUN. 2017;206(5):379-382.

Effect of antiviral therapy for HCV on lipid levels
Mauss S, Berger F, Wehmeyer M, Ingiliz P, Hueppe D, Lutz T, Simon K, Schewe K, Rockstroh J, Baumgarten A, Christensen S
ANTIVIR THER. 2017;21(1):81-88.

Factors associated with long-term survival after liver Transplantation, a retrospective cohort study
Pischke S, Lege M, von Wulffen M, Galante A, Otto B, Wehmeyer M, Herden U, Fischer L, Nashan B, Lohse A, Sterneck M
WORLD J HEPATOL. 2017;9(8):427-435.

Anti-TNF-α for necrotizing sarcoid granulomatosis of the liver
Sebode M, Weidemann S, Wehmeyer M, Lohse A, Schramm C
HEPATOLOGY. 2017;65(4):1410-1412.

Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation
Wehmeyer M, Dammermann W, Seiz O, Zinser M, Galante A, Lohse A, Sterneck M, Nashan B, Herden U, Lüth S
PANCREATOLOGY. 2017;17(6):898-904.

Infections complicating severe alcoholic Hepatitis: Enterococcus species represent the most frequently identified pathogen
Beisel C, Blessin U, Schulze Zur Wiesch J, Wehmeyer M, Lohse A, Benten D, Kluwe J
SCAND J GASTROENTERO. 2016;51(7):807-13.

Acute Hepatitis E: Two Sides of the Same Coin
Hartl J, Wehmeyer M, Pischke S
VIRUSES-BASEL. 2016;8(11):E299.

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, Schmutz G, Wehmeyer M, Boesecke C, Simon K, Berger F, Rockstroh J, Schulze zur Wiesch J, Baumgarten A, Mauss S
CLIN INFECT DIS. 2016;63(10):1320-1324.

New findings in HCV genotype distribution in selected West European, Russian and Israeli regions
Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S
J CLIN VIROL. 2016;81:82-9.

Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern
Wehmeyer M, Zyriax B, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse A, Kluwe J
MEDICINE. 2016;95(23):e3887.

High Rate of Cardiac Abnormalities in a Postmortem Analysis of Patients Suffering From Liver Cirrhosis
Wehmeyer M, Heuer A, Benten D, Püschel K, Sydow K, Lohse A, Lüth S
J CLIN GASTROENTEROL. 2015;49(10):866-872.

Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
Wehmeyer M, Jordan S, Lüth S, Hartl J, Stoehr A, Eißing C, Lohse A, Petersen J, Buggisch P, Schulze zur Wiesch J
DIGEST LIVER DIS. 2015;47(9):811-814.

Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection
Wehmeyer M, Eißing F, Jordan S, Röder C, Hennigs A, Degen O, Hüfner A, Hertling S, Schmiedel S, Sterneck M, Lunzen J, Lohse A, Schulze Zur Wiesch J, Lüth S

Prediction of spontaneous bacterial peritonitis in cirrhotic ascites by a simple scoring system
Wehmeyer M, Krohm S, Kastein F, Lohse A, Lüth S
SCAND J GASTROENTERO. 2014;49(5):595-603.

Some unusual cystic lesions of the liver
Wehmeyer M, Lohse A, Schramm C
GASTROENTEROLOGY. 2013;145(6):e1-2.

Letzte Aktualisierung aus dem FIS: 23.05.2024 - 00:36 Uhr